Table 1.
Clinicopathological data of human postmortem tissue samples used for in situ hybridization and immunohistochemistrya
| Subject no. | Diagnosis | Sex | Age (yr) | PMI (h) | pH | BW (g) | RIN | Cause of death |
|---|---|---|---|---|---|---|---|---|
| 00–115 | PD/DEM | Male | 70 | 9:05 | 6.33 | 1258 | 6.2 | Pneumonia, septic shock |
| 04–045 | PD/DEM | Male | 71 | 6:58 | 6.55 | 1358 | 8.4* | Pneumonia |
| 00–139 | PD/DEM | Male | 72 | 7:15 | 6.55 | 1546 | 6.7 | Uremia |
| 02–003 | PD | Female | 75 | 5:00 | 6.52 | 1218 | 9.6* | Euthanasia |
| 02–011 | PD | Female | 79 | 5:45 | 6.37 | 1203 | 8.7* | Myocardial infraction |
| 00–034 | PD | Male | 86 | 8:30 | 6.52 | 1178 | 9.2* | Unknown |
| 02–064 | PD | Male | 87 | 7:20 | 6.37 | 1166 | 7.4 | Respiratory insufficiency |
| 98–126 | CTRL | Male | 71 | 6:00 | 6.54 | 1385 | 8.8 | Respiratory insufficiency |
| 00–049 | CTRL | Male | 78 | 6:55 | 6.42 | 1332 | 9.2* | Cardiac failure |
| 97–144 | CTRL | Male | 78 | 4:00 | 6.43 | 1160 | 9* | Pulmonary carcinoma |
| 00–142 | CTRL | Female | 82 | 5:30 | 6.60 | 1280 | 9.2* | Myocardial infarct |
| 00–022 | CTRL | Female | 83 | 7:45 | 6.52 | 1102 | 9.2* | Acute myocardial infraction |
| 98–062 | CTRL | Male | 85 | 4:35 | 6.95 | 1332 | 7.5 | Respiratory insufficiency |
| 99–046 | CTRL | Female | 89 | 5:10 | 6.62 | 1168 | 9.5 | Cardiac arrest |
| 01–029 | CTRL | Female | 90 | 5:25 | 6.58 | 1066 | 7.6 | Myocardial infraction |
| 00–050 | CTRL | Female | 52 | 6:50 | 7.16 | 1258 | — | Leiomyosarcoma with metastasis |
aAll brain tissue was collected from donors from whose written informed consent for a brain autopsy and the use of the material and clinical information for research purposes had been obtained by the NBB. For further diagnosis, an extensive neuropathological investigation was performed on all PD and control tissue. Control tissue did not present any Braak pathology score for neurofibrillary tangles >2 (Braak et al., 2003), and neither control nor PD subject had a known history of neurological or psychiatric disease other than PD or PD-related dementia. All PD patients received dopamine replacement therapy during the course of the disease. CTRL, Control; PD/DEM, Parkinson's disease with dementia; PMI, postmortem interval; BW, brain weight; RIN, RNA integrity number.
*Sample used in the microarray study. All samples, except Subject 00–050, were used for qPCR analysis as described previously (Bossers et al., 2009). Subject 00–050 was only used for in situ hybridization.